Despite clearly favorable effects on the lipoprotein profile, pharmacological CETP inhibitors, such as torcetrapib,12 dalcetrapib13 and evacetrapib,14 failed to show clinical benefit on cardiovascular disease outcomes including atherosclerosis and vascular inflammation. This evidence concerns the gene CETP and cardiovascular disorder.